000130805 001__ 130805
000130805 005__ 20240228145554.0
000130805 0247_ $$2doi$$a10.1038/leu.2017.92
000130805 0247_ $$2pmid$$apmid:28322237
000130805 0247_ $$2ISSN$$a0887-6924
000130805 0247_ $$2ISSN$$a1476-5551
000130805 0247_ $$2altmetric$$aaltmetric:20917080
000130805 037__ $$aDKFZ-2017-05883
000130805 041__ $$aeng
000130805 082__ $$a610
000130805 1001_ $$0P:(DE-He78)ce3cd0df5fbbdf8768f6f1cd543bce72$$aKayser, Sabine$$b0$$eFirst author$$udkfz
000130805 245__ $$aCharacteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
000130805 260__ $$aBasingstoke$$bNature Publ. Group$$c2017
000130805 3367_ $$2DRIVER$$aarticle
000130805 3367_ $$2DataCite$$aOutput Types/Journal article
000130805 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525863094_13985
000130805 3367_ $$2BibTeX$$aARTICLE
000130805 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130805 3367_ $$00$$2EndNote$$aJournal Article
000130805 520__ $$aTherapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated 103 adult t-APL patients undergoing treatment with all-trans retinoic acid (ATRA) alone (n=7) or in combination with ATO (n=24), CTX (n=53), or both (n=19). Complete remissions were achieved after induction therapy in 57% with ATRA, 100% with ATO/ATRA, 78% with CTX/ATRA, and 95% with CTX/ATO/ATRA. Early death rates were 43% for ATRA, 0% for ATO/ATRA, 12% for CTX/ATRA and 5% for CTX/ATO/ATRA. Three patients relapsed, two developed therapy-related acute myeloid leukemia and 13 died in remission including seven patients with recurrence of the prior malignancy. Median follow-up for survival was 3.7 years. None of the patients treated with ATRA alone survived beyond one year. Event-free survival was significantly higher after ATO-based therapy (95%, 95% CI, 82-99%) as compared to CTX/ATRA (78%, 95% CI, 64-87%; P=0.042), if deaths due to recurrence of the prior malignancy were censored. The estimated 2-year overall survival in intensively treated patients was 88% (95% CI, 80-93%) without difference according to treatment (P=0.47). ATO when added to ATRA or CTX/ATRA is feasible and leads to better outcomes as compared to CTX/ATRA in t-APL.
000130805 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130805 588__ $$aDataset connected to CrossRef, PubMed,
000130805 7001_ $$0P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aKrzykalla, J.$$b1$$udkfz
000130805 7001_ $$aElliott, M. A.$$b2
000130805 7001_ $$aNorsworthy, K.$$b3
000130805 7001_ $$aGonzales, P.$$b4
000130805 7001_ $$aHills, R. K.$$b5
000130805 7001_ $$aBaer, M. R.$$b6
000130805 7001_ $$aRáčil, Z.$$b7
000130805 7001_ $$aMayer, J.$$b8
000130805 7001_ $$aNovak, J.$$b9
000130805 7001_ $$aŽák, P.$$b10
000130805 7001_ $$aSzotkowski, T.$$b11
000130805 7001_ $$aGrimwade, D.$$b12
000130805 7001_ $$aRussell, N. H.$$b13
000130805 7001_ $$aWalter, R. B.$$b14
000130805 7001_ $$aEstey, E. H.$$b15
000130805 7001_ $$aWestermann, J.$$b16
000130805 7001_ $$aGörner, M.$$b17
000130805 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, A.$$b18$$udkfz
000130805 7001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, A.$$b19$$udkfz
000130805 7001_ $$aSmith, B. D.$$b20
000130805 7001_ $$aBurnett, A. K.$$b21
000130805 7001_ $$aThiede, C.$$b22
000130805 7001_ $$aRöllig, C.$$b23
000130805 7001_ $$aHo, A. D.$$b24
000130805 7001_ $$aEhninger, G.$$b25
000130805 7001_ $$0P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aSchlenk, Richard$$b26$$udkfz
000130805 7001_ $$aTallman, M. S.$$b27
000130805 7001_ $$aLevis, M. J.$$b28
000130805 7001_ $$aPlatzbecker, U.$$b29
000130805 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/leu.2017.92$$gVol. 31, no. 11, p. 2347 - 2354$$n11$$p2347 - 2354$$tLeukemia$$v31$$x1476-5551$$y2017
000130805 909CO $$ooai:inrepo02.dkfz.de:130805$$pVDB
000130805 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ce3cd0df5fbbdf8768f6f1cd543bce72$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130805 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130805 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000130805 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000130805 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aDeutsches Krebsforschungszentrum$$b26$$kDKFZ
000130805 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130805 9141_ $$y2017
000130805 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130805 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130805 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2015
000130805 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130805 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130805 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130805 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130805 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130805 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130805 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130805 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130805 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130805 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bLEUKEMIA : 2015
000130805 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x0
000130805 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000130805 9201_ $$0I:(DE-He78)G040-20160331$$kG040$$lKlinische Studienzentrale$$x2
000130805 980__ $$ajournal
000130805 980__ $$aVDB
000130805 980__ $$aI:(DE-He78)G330-20160331
000130805 980__ $$aI:(DE-He78)C060-20160331
000130805 980__ $$aI:(DE-He78)G040-20160331
000130805 980__ $$aUNRESTRICTED